Standard Operating Procedure for Internal Communication of New Regulatory Requirements
| Department | Regulatory Affairs |
| SOP No. | RA/2026/640 |
| Supersedes | NA |
| Page No. | 1 of X |
| Issue Date | 09/04/2026 |
| Effective Date | 09/04/2026 |
| Review Date | 09/04/2028 |
Purpose
This Standard Operating Procedure (SOP) defines the systematic approach for identifying, assessing, and internally communicating new regulatory requirements to all relevant departments and personnel. The objective is to ensure timely awareness, understanding, and implementation of changes in regulations, guidelines, or policies affecting the organization’s compliance status and operational activities.
Scope
This SOP applies to all new or updated regulatory information related to pharmaceutical products, processes, quality systems, manufacturing, quality assurance, laboratory operations, documentation, engineering, utilities, warehousing, and compliance activities within the company. It covers internal dissemination of regulatory changes originating from health authorities, pharmacopoeias, or industry standards. This SOP excludes external communication with regulatory authorities or third-party stakeholders.
Responsibilities
- Regulatory Affairs Team: Identify, collect, and assess new regulatory requirements; prepare communication materials.
- Department Heads: Review communications, cascade information within their teams, and ensure implementation.
- Quality Assurance: Verify alignment of communicated changes with quality systems and compliance obligations.
- Document Control: Manage documentation updates and issuance related to regulatory changes.
- Training Department: Facilitate awareness and compliance training based on communicated requirements.
Accountability
The head of Regulatory Affairs is accountable for ensuring consistent implementation, ongoing compliance, periodic effectiveness reviews, and escalation of issues related to the internal communication of new regulatory requirements. The role oversees timely dissemination, documentation control, and ensures that corrective actions are taken if communication lapses occur.
Procedure
1. Identification and Collection: Regulatory Affairs monitors official sources such as regulatory authority websites, industry bulletins, pharmacopoeial updates, and official publications daily or as they are released. New or revised regulatory requirements are logged in the Regulatory Requirements Register (Annexure-1).
2. Preliminary Assessment: The Regulatory Affairs team conducts an initial review of the new requirements to understand their applicability, urgency, risk impact, and affected departments or processes. Engage subject matter experts as needed for technical interpretation.
3. Preparation of Communication Package: Prepare a clear and concise summary document outlining the key changes, deadlines for compliance, impacts, and necessary actions. This document may include checklists or guidelines to facilitate understanding (see Annexure-2).
4. Management Review: Submit the summary document to the Regulatory Affairs Manager and QA Head for review and approval prior to distribution. Any discrepancies or needed clarifications must be resolved before communication.
5. Internal Distribution: Regulatory Affairs communicates the approved information through defined channels such as email notifications, intranet postings, team meetings, or formal memos. The communication is directed to all impacted departments, ensuring coverage of manufacturing, QC, QA, engineering, documentation, and other relevant functional areas.
6. Awareness and Training: Collaborate with the Training Department to develop and conduct awareness sessions or specific trainings if the regulatory changes affect standard operating procedures, processes, or compliance obligations. Attendance records and training effectiveness assessments are maintained.
7. Implementation Monitoring: Department heads monitor implementation of changes within their teams, ensuring all corrective or preventive actions are completed on time. Any challenges or deviations are documented and escalated.
8. Documentation and Record Keeping: Archive all communication records, approvals, training attendance logs, and implementation evidence in controlled repositories. Maintain the Regulatory Requirements Register and Training Records for auditing and review purposes.
9. Periodic Review: Regulatory Affairs conducts periodic reviews (at least annually) to assess the effectiveness of communication and implementation. Updates to this SOP are made based on observations, audit findings, or regulatory changes.
10. Deviation and Escalation: Any failure to communicate, delayed implementation, or compliance gaps must be reported immediately to the Regulatory Affairs Head. Corrective actions must be initiated, documented, and tracked to closure.
This procedure ensures robust, compliant, and timely dissemination of regulatory intelligence, supporting organizational adherence to evolving regulatory landscapes and continuous GMP compliance.
Abbreviations
- QA: Quality Assurance
- QC: Quality Control
- SOP: Standard Operating Procedure
- GMP: Good Manufacturing Practice
- RA: Regulatory Affairs
- CAPA: Corrective and Preventive Action
- ICH: International Council for Harmonisation
Documents
- Regulatory Requirements Register (Annexure-1)
- New Regulatory Requirement Communication Summary (Annexure-2)
References
- EU GMP Annex 11 – Computerized Systems
- ICH Q9 – Quality Risk Management
- FDA Guidance for Industry – Regulatory Submissions
- WHO GMP Guidelines
- Internal Quality Management System documentation and policies
Version
1.0
Approval
| Prepared By | |
| Checked By | |
| Approved By |
Annexures
Annexure-1: Regulatory Requirements Register
| Date Identified | Source | Requirement Title | Summary | Responsible Department(s) | Status |
|---|---|---|---|---|---|
| 05/04/2026 | Health Authority Website | Revision of Stability Testing Guidelines | New requirements for long-term stability data on drug substances | QA, QC, Regulatory Affairs | Communicated |
| 07/04/2026 | Pharmacopoeial Update | Monograph Amendment for Injectable Products | Change in impurity limits and testing protocols | QC, Manufacturing, Regulatory Affairs | Pending Review |
Annexure-2: New Regulatory Requirement Communication Summary
| Document No.: | RA/NR/2026/04 |
| Issue Date: | 09/04/2026 |
| Title: | Revision of Stability Testing Guidelines – Key Updates |
| Summary of Change: | The health authority has issued updated guidelines requiring additional long-term stability data for drug substances. Extended testing periods up to 36 months must be documented. |
| Effective Date for Compliance: | 01/07/2026 |
| Impacted Departments: | QA, QC, Regulatory Affairs, Manufacturing |
| Required Actions: | Update stability protocols, retrain lab personnel, and document compliance evidence. |
| Contact for Queries: | Regulatory Affairs Team |
| Approval: | Approved as per SOP by QA and RA Management |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
| 09/04/2026 | 1.0 | Initial issue | New SOP creation |